CN103223131A - 肝病药物 - Google Patents
肝病药物 Download PDFInfo
- Publication number
- CN103223131A CN103223131A CN2013101749145A CN201310174914A CN103223131A CN 103223131 A CN103223131 A CN 103223131A CN 2013101749145 A CN2013101749145 A CN 2013101749145A CN 201310174914 A CN201310174914 A CN 201310174914A CN 103223131 A CN103223131 A CN 103223131A
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- liver
- disease drug
- liver disease
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 101
- 208000019423 liver disease Diseases 0.000 title claims abstract description 83
- 229940079593 drug Drugs 0.000 title claims abstract description 74
- 230000000694 effects Effects 0.000 abstract description 54
- 210000004185 liver Anatomy 0.000 abstract description 32
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract description 13
- 208000006454 hepatitis Diseases 0.000 abstract description 12
- 210000003734 kidney Anatomy 0.000 abstract description 12
- 208000005176 Hepatitis C Diseases 0.000 abstract description 11
- 241000700605 Viruses Species 0.000 abstract description 10
- 102000014150 Interferons Human genes 0.000 abstract description 9
- 108010050904 Interferons Proteins 0.000 abstract description 9
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract description 9
- 229940079322 interferon Drugs 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 208000005252 hepatitis A Diseases 0.000 abstract description 8
- 206010059193 Acute hepatitis B Diseases 0.000 abstract description 6
- 208000037628 acute hepatitis B virus infection Diseases 0.000 abstract description 6
- 238000005728 strengthening Methods 0.000 abstract description 6
- 208000006154 Chronic hepatitis C Diseases 0.000 abstract description 5
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 206010019755 Hepatitis chronic active Diseases 0.000 abstract description 5
- 206010019759 Hepatitis chronic persistent Diseases 0.000 abstract description 5
- 229940088598 enzyme Drugs 0.000 abstract description 5
- 230000001965 increasing effect Effects 0.000 abstract description 5
- 230000001717 pathogenic effect Effects 0.000 abstract description 5
- 102000016943 Muramidase Human genes 0.000 abstract description 4
- 108010014251 Muramidase Proteins 0.000 abstract description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 abstract description 4
- 231100000283 hepatitis Toxicity 0.000 abstract description 4
- 210000000265 leukocyte Anatomy 0.000 abstract description 4
- 229960000274 lysozyme Drugs 0.000 abstract description 4
- 239000004325 lysozyme Substances 0.000 abstract description 4
- 235000010335 lysozyme Nutrition 0.000 abstract description 4
- 210000001541 thymus gland Anatomy 0.000 abstract description 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 230000029812 viral genome replication Effects 0.000 abstract description 3
- 102000000588 Interleukin-2 Human genes 0.000 abstract description 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000257303 Hymenoptera Species 0.000 abstract 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 240000000038 Ziziphus mauritiana Species 0.000 abstract 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 abstract 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 40
- 208000002672 hepatitis B Diseases 0.000 description 32
- 208000024891 symptom Diseases 0.000 description 32
- 230000003908 liver function Effects 0.000 description 28
- 241001251068 Formica fusca Species 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 239000007788 liquid Substances 0.000 description 16
- 241000190633 Cordyceps Species 0.000 description 13
- 239000009636 Huang Qi Substances 0.000 description 13
- 108010082126 Alanine transaminase Proteins 0.000 description 12
- 230000001154 acute effect Effects 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 206010019799 Hepatitis viral Diseases 0.000 description 10
- 108090000340 Transaminases Proteins 0.000 description 10
- 102000003929 Transaminases Human genes 0.000 description 10
- 201000001862 viral hepatitis Diseases 0.000 description 10
- 241000700721 Hepatitis B virus Species 0.000 description 9
- 230000036528 appetite Effects 0.000 description 9
- 235000019789 appetite Nutrition 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 206010003445 Ascites Diseases 0.000 description 8
- 206010023126 Jaundice Diseases 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 7
- 230000004596 appetite loss Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000019017 loss of appetite Diseases 0.000 description 7
- 235000021266 loss of appetite Nutrition 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000002443 hepatoprotective effect Effects 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 235000019636 bitter flavor Nutrition 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 210000003786 sclera Anatomy 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 208000037319 Hepatitis infectious Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000010183 Thymus Hyperplasia Diseases 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012744 reinforcing agent Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000323799 Bat Hepatitis B virus Species 0.000 description 1
- 241000255791 Bombyx Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001489978 Eupolyphaga Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010052989 Naphthol AS D Esterase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000012876 acute enteritis Diseases 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002558 medical inspection Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310174914.5A CN103223131B (zh) | 2013-05-13 | 2013-05-13 | 肝病药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310174914.5A CN103223131B (zh) | 2013-05-13 | 2013-05-13 | 肝病药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103223131A true CN103223131A (zh) | 2013-07-31 |
CN103223131B CN103223131B (zh) | 2014-10-08 |
Family
ID=48833927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310174914.5A Active CN103223131B (zh) | 2013-05-13 | 2013-05-13 | 肝病药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103223131B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105056022A (zh) * | 2015-07-30 | 2015-11-18 | 吴斌 | 一种用于治疗肝硬化的药物 |
CN105816571A (zh) * | 2016-03-31 | 2016-08-03 | 覃淑兰 | 一种护肝的中药组合物及其制备方法 |
CN107050352A (zh) * | 2017-03-08 | 2017-08-18 | 重庆多普泰制药股份有限公司 | 一种治疗慢性乙型肝炎的中药组合物 |
CN109925470A (zh) * | 2017-12-19 | 2019-06-25 | 深圳市中医院 | 一种治疗乙肝肝硬化的益气软肝中药组合物 |
CN112568424A (zh) * | 2019-09-30 | 2021-03-30 | 深圳市华韵生物科技产业有限公司 | 一种调理肝病的食品 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1113779A (zh) * | 1994-06-17 | 1995-12-27 | 殷广全 | 抗乙肝制剂 |
CN1280841A (zh) * | 1999-07-01 | 2001-01-24 | 陶杰 | 一种治疗乙肝及类风湿的药物 |
CN1876062A (zh) * | 2006-04-28 | 2006-12-13 | 钟龙 | 治乙型肝炎、肝硬化的中药的制备方法及其制备的中药 |
-
2013
- 2013-05-13 CN CN201310174914.5A patent/CN103223131B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1113779A (zh) * | 1994-06-17 | 1995-12-27 | 殷广全 | 抗乙肝制剂 |
CN1280841A (zh) * | 1999-07-01 | 2001-01-24 | 陶杰 | 一种治疗乙肝及类风湿的药物 |
CN1876062A (zh) * | 2006-04-28 | 2006-12-13 | 钟龙 | 治乙型肝炎、肝硬化的中药的制备方法及其制备的中药 |
Non-Patent Citations (2)
Title |
---|
台银科 等: "自拟虫草蚂蚁散治疗慢性乙型肝炎68例疗效观察", 《宁夏医学杂志》 * |
黄贵兴: "慢性乙型肝炎中医治疗近况", 《黑龙江中医药》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105056022A (zh) * | 2015-07-30 | 2015-11-18 | 吴斌 | 一种用于治疗肝硬化的药物 |
CN105816571A (zh) * | 2016-03-31 | 2016-08-03 | 覃淑兰 | 一种护肝的中药组合物及其制备方法 |
CN107050352A (zh) * | 2017-03-08 | 2017-08-18 | 重庆多普泰制药股份有限公司 | 一种治疗慢性乙型肝炎的中药组合物 |
CN109925470A (zh) * | 2017-12-19 | 2019-06-25 | 深圳市中医院 | 一种治疗乙肝肝硬化的益气软肝中药组合物 |
CN112568424A (zh) * | 2019-09-30 | 2021-03-30 | 深圳市华韵生物科技产业有限公司 | 一种调理肝病的食品 |
Also Published As
Publication number | Publication date |
---|---|
CN103223131B (zh) | 2014-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102038758B (zh) | 治疗风湿病的风湿病制剂 | |
CN102178800B (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法 | |
CN103301412A (zh) | 一种治疗酒精肝的中药组合物 | |
CN102727686A (zh) | 一种治疗脂肪肝中药组合物 | |
CN103223131B (zh) | 肝病药物 | |
CN102772704B (zh) | 老年病药物 | |
CN102166278B (zh) | 一种治疗小儿类风湿性关节炎的中药组合物及其制备方法 | |
CN102210820A (zh) | 一种治疗白血病的中药组合物 | |
CN103223118A (zh) | 一种治疗面瘫的中药组合物 | |
CN103041256B (zh) | 一种治疗小儿反复呼吸道感染的中药制剂 | |
CN103301267A (zh) | 一种治疗高血压和/或动脉粥样硬化的中药组合物及应用 | |
CN102847061B (zh) | 一种治疗小儿病毒性心肌炎的中药制剂及其制备方法 | |
CN102698207A (zh) | 一种治疗肝病的中药组合物及其制备方法 | |
CN105943705A (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法 | |
CN103041255B (zh) | 治疗小儿咽喉肿痛呼吸道感染的中药制剂 | |
CN101912596A (zh) | 一种治疗过敏性鼻炎的药物及其制备方法 | |
CN104606514A (zh) | 一种治疗肾虚型耳鸣的中药组合物 | |
CN103479835A (zh) | 一种治疗肝硬化的中药 | |
CN103393986A (zh) | 一种治疗乙肝肝硬化的中药组合物及其制备方法 | |
CN105106634A (zh) | 一种治疗急性阑尾炎的中药制剂及其应用 | |
CN101199667A (zh) | 一种治疗白血病、再生障碍性贫血的中药制剂 | |
CN1471956A (zh) | 补髓生血颗粒及其制备方法 | |
CN103611035A (zh) | 一种治疗痰湿内阻型脂肪肝的中药组合物 | |
CN103041258B (zh) | 治疗小儿呼吸道感染伴纳差不食的中药制剂 | |
CN102772665B (zh) | 一种治疗阴虚内热型病毒性心肌炎的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN RIYUESHEN BIO-TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: YIN GUANGQUAN Effective date: 20150618 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150618 Address after: 518000, Guangdong province Shenzhen Longgang District Bantian street two Hao road 28 No. Patentee after: Shenzhen sun god Biotechnology Co., Ltd. Address before: 518129 Guangdong city of Shenzhen province Futian District Whampoa Nga Chui did Park 6 Patentee before: Yin Guangquan |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 518000, Guangdong province Shenzhen Longgang District Bantian street two Hao road 28 No. Patentee after: Shenzhen sun and moon god biological Polytron Technologies Inc Address before: 518000, Guangdong province Shenzhen Longgang District Bantian street two Hao road 28 No. Patentee before: Shenzhen sun god Biotechnology Co., Ltd. |